Microdosing vs SSRIs: A Psychiatrist’s Take on the Future of Depression Treatment

Explore the evolving landscape of mental health treatments in this live webinar with Dr. Dave Rabin, M.D., Ph.D., board-certified psychiatrist and neuroscientist. We dive into the intersection of microdosing, psychedelics, and traditional SSRIs, comparing stabilization-focused approaches with the transformative potential of psychedelic medicine. Whether you’re a mental health professional or someone seeking alternatives to conventional pharmaceuticals, this session offers practical, science-backed insights for nervous system regulation, emotional resilience, and safe transitions.

Inside This Conversation

Mechanisms of Action: Stabilization vs. Expansion
See how SSRIs “buffer” severe depression by limiting emotional range, versus psychedelics, which act at receptors like 5HT2A to potentially reset emotional processing and broaden awareness.

‍

The Safety Gap and Serotonin Syndrome
Learn why combining classic psychedelics with SSRIs can be risky, and how guided tapering is essential to keep patients safe.

‍

Unlocking Neuroplasticity and Critical Windows
Understand the heightened 72-hour neuroplasticity window after a full-dose psychedelic session, and how microdosing can help reinforce healthier neural pathways.

‍

A New Toolkit for Recovery
Practical strategies for supporting the nervous system during transitions, including non-judgmental listening, vagal nerve stimulation, and wearable tech like Apollo Neuro to maintain safety and balance.

‍

Navigating Mushroom Strains and Anxiety
Insights on how different psilocybin strains—like Golden Teachers vs. Penis Envy—can influence self-reflection, anxiety management, and microdosing experiences.